James Davis

54PUBLICATIONS
163CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)ChiropracticPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (54)

|Aug 07, 2026
Prophylactic tocilizumab for bispecific T-cell engagers in multiple myeloma: current evidence and clinical considerations for mitigating cytokine release syndrome.

|Jul 02, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

|Jun 16, 2026
Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma.

|May 18, 2026
Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Feb 27, 2026
Discrepancy in Estimating GFR for Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant: A Retrospective Analysis.

Benjamin Teruel, Ashley L Golbus, Elaine Park

Pageof 9

Frequent Collaborators

20 joint publications

Jack Khouri

16 joint publications

Surbhi Sidana

16 joint publications

Larry D Anderson

15 joint publications

Danai Dima